- Conditions
- Healthy Volunteers
- Interventions
- E2086
- Drug
- Lead sponsor
- Eisai Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Austin, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Healthy, Men, Male Contraception
- Interventions
- Dimethandrolone-Undecanoate, Levonorgestrel 0.03 MG, Placebo oral capsule
- Drug
- Lead sponsor
- Premier Research
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 92 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 2
- States / cities
- Torrance, California • Seattle, Washington
- Conditions
- HIV, Immune Cells (Mucosal and Systemic), Contraception
- Interventions
- levonorgestrel exposure, DMPA exposure, etonogestrel exposure, IUD insertion, subdermal contraceptive implant insertion
- Drug · Device
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 34 Years · Female only
- Enrollment
- 326 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Colorectal Cancer, Early Onset Colorectal Cancer, Diet Habit, Risk Reduction
- Interventions
- Semi Quantitative Food Frequency Questionnaire (SQFFQ)
- Behavioral
- Lead sponsor
- San Raffaele University
- Other
- Eligibility
- 18 Years to 49 Years
- Enrollment
- 2,300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2035
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Chicago, Illinois
- Conditions
- Oral Contraceptive
- Interventions
- Oral Contraceptive: Ortho-Novum® 1/35, Oral Contraceptive: Ovcon® 35, Oral Contraceptive: Microgestin Fe® 1/20
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 82 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pharmacokinetics
- Interventions
- Lurasidone 40 mg, Placebo 40 mg, Ortho Tri-Cyclen
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Acne Vulgaris
- Interventions
- drospirenone and ethinyl estradiol, Placebo tablet
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Healthy Adult Premenopausal Female Volunteers
- Interventions
- ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day
- Drug
- Lead sponsor
- Intarcia Therapeutics
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Follicle Development, Ovarian Follicle, Follicle Count, Follicle Size, Oral Contraceptive
- Interventions
- Desogestrel/ethinyl estradiol and ethinyl estradiol, 28-day drospirenone oral contraceptive, 28-day levonorgestrel oral contraceptive
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 206 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Philadelphia, Pennsylvania • Seattle, Washington
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Continuous Glucose Monitor
- Device
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Healthy
- Interventions
- Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
- Drug · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 25 Years to 55 Years · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Contraception
- Interventions
- Norethindrone/ethinyl estradiol
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 1,700 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007 – 2009
- U.S. locations
- 63
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 53 more
- Conditions
- Teen Sexual Health
- Interventions
- text message intervention
- Behavioral
- Lead sponsor
- Denver Health and Hospital Authority
- Other
- Eligibility
- 13 Years to 18 Years · Female only
- Enrollment
- 244 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
- Interventions
- Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 40 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Wauwatosa, Wisconsin
- Conditions
- Contraception, Hypogonadism
- Interventions
- Oral Testosterone, Leuprolide (Lupron), Dutasteride
- Drug
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 50 Years · Male only
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2006
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Inflammatory Bowel Diseases, Contraception, Menstrual Problem
- Interventions
- Proposed study design and randomization scenarios, Repeated measures of validated Inflammatory Bowel Disease Patient Reported Outcome Instruments, Inflammatory marker collection and assessment for correlation with PRO responses and menstrual timing
- Other
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Healthy Volunteers
- Interventions
- Obicetrapib, Obicetrapib + Drospirenone / Ethinyl Estradiol (COC), Drospirenone / Ethinyl Estradiol (COC)
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
- Conditions
- HIV Infections
- Interventions
- Ortho Tri-Cyclen LO, Ortho Cyclen, Ortho Cyclen + Efavirenz
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2007
- U.S. locations
- 2
- States / cities
- San Diego, California • Tacoma, Washington
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Ortho-Cyclen, Dulaglutide
- Drug · Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Initiation of Oral Contraception (OC), Initiation of Depo-Provera (DMPA), Initiation of Mirena (LNG-IUD)
- Interventions
- Mirena, Oral contraception, Depo-Provera
- Drug
- Lead sponsor
- Thomas Cherpes, DVM, MD
- Other
- Eligibility
- 15 Years to 25 Years · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Overweight
- Interventions
- LY3437943, Ethinyl Estradiol, Drospirenone
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 40 Years to 60 Years · Female only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- South Miami, Florida • San Antonio, Texas
- Conditions
- Premenstrual Syndrome, PMS, Premenstrual Dysphoric Disorder, PMDD, Depression
- Interventions
- Ethinyl Estradiol/Drospirenone, Placebo, CDB 2914
- Drug
- Lead sponsor
- National Institute of Mental Health (NIMH)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Nicotine Dependence, Contraception
- Interventions
- Low-dose Progesterone, High-dose Progesterone
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 95 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2017
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Polycystic Ovary Syndrome, Metabolic Syndrome
- Interventions
- flutamide, ethinyl estradiol 35 mcg and drospirenone 3 mg, placebo
- Drug · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois